



# Immunotoxicity of asbestos

Jean C. Pfau

## Abstract

The study of asbestos immunotoxicity is generally applied toward understanding the mechanisms that lead to its infamous outcomes, mesothelioma and asbestosis, rather than as an outcome itself. However, emerging evidence suggests that asbestos exposure has critical inflammatory and autoimmune effects. Although crystalline silica is broadly accepted as an exposure trigger for systemic autoimmune diseases (SAID), the literature supporting asbestos as another SAID trigger is limited. Challenges for establishing causality between asbestos exposure and autoimmunity include small, often occupationally-exposed cohorts, a tendency to focus on carcinogenicity or lung pathology, and poor characterization of fiber type in a given exposure scenario. However, a growing set of studies strongly supports inclusion of amphibole asbestos (AA) as an environmental trigger for autoimmunity. Both human and animal studies have revealed that AA, but not the common commercial asbestos (chrysotile), drives auto-antibody production, alters cytokine profiles, and is associated with autoimmune disease. The potential public health impact of these findings are highlighted in the growing awareness of “naturally occurring asbestos” in geographic locations where it was not previously predicted to occur, leading to environmental exposures in wide areas of the world as a component of dust. As climate change brings warmer and dryer conditions to the more arid parts of the world, wind-blown mineral dusts containing asbestos may become more common. It is essential that epidemiologists, clinicians and regulatory agencies become aware of this emerging risk to health by an environmental immunotoxicant.

## Addresses

Montana State University, Department of Microbiology and Immunology, 960 Technology Blvd, Bozeman, MT 59718, USA

Corresponding author: Pfau, Jean C. ([Jean.pfau@montana.edu](mailto:Jean.pfau@montana.edu))

**Current Opinion in Toxicology** 2018, 10:1–7

This review comes from a themed issue on **Systems Toxicology: Immunotoxicity**

Available online 14 November 2017

For a complete overview see the [Issue](#) and the [Editorial](#)

<https://doi.org/10.1016/j.cotox.2017.11.005>

2468-2020/© 2017 Elsevier B.V. All rights reserved.

## Keywords

Environmental, Autoimmunity, Naturally occurring asbestos (NOA), Pleural fibrosis, Libby amphibole.

## Abbreviations

ANA, antinuclear autoantibodies; AA, amphibole asbestos; ARD, asbestos-related diseases; ATSDR, Agency for Toxic Substances and Disease Registry; CARD, Center for Asbestos Related Diseases (Libby, MT); CDC, Center for Disease Control (and Prevention); EPA,

Environmental Protection Agency; LA, Libby Amphibole; NOA, naturally occurring asbestos; SAID, systemic autoimmune diseases; SLE, systemic lupus erythematosus, aka lupus.

## 1. Introduction

Asbestos is a fibrous mineral that is highly resistant to destruction by heat or other forces. It has been used commercially for decades, providing valuable materials for insulation, brake linings, and construction. It continues to be mined in several countries and used in manufactured products around the world, including the United States. The term “asbestos” historically refers only to commercial fibers in two families, serpentine (chrysotile) and amphibole asbestos (AA). The commercial amphiboles include only five types of fibers, classified for purposes of understanding their properties related to extraction and materials fabrication. In this review, however, the term is used more broadly, to include not only the regulated commercial forms but also the unregulated fibers that have similar properties.

The majority of research performed on asbestos has studied only the commercial forms of asbestos and has focused on cancer and asbestosis as outcomes of occupational exposures. Due to new discoveries, this limited research scope is no longer appropriate [1,2]. Fibrous minerals not previously classified as asbestos must now be recognized as a part of the human “exposome”, a component of lifetime exposures that may impact health. There are several non-occupational exposure pathways occurring world-wide from airborne release [3]. Such exposures carry risk even at low concentrations of fibers released from rocks and soils by construction, road building, recreation, or dust storms [3–6]. This is becoming a highly significant public health issue, especially in arid regions such as the southwestern United States due to a combination of increased population growth, development, and increasing aridity caused by climate change [7].

## 2. Paradigm shifts: mineral fiber terminology and non-cancer outcomes

Research on environmental asbestos exposures has revealed the need to distinguish between the two families of asbestos. Chrysotile asbestos is well known as the most common commercial form of asbestos, due to its ability to be woven into many kinds of materials. Therefore, regulatory standards for asbestos are based largely on occupational exposures to chrysotile, which is known to increase risk for mesothelioma, pulmonary carcinoma, and interstitial fibrosis (asbestosis). However, it seems to be less pathogenic than amphibole

asbestos (AA) [8], which makes up many of the known environmental exposures. The immunotoxicity of chrysotile appears to be quite distinct from that of AA [9], leading to different health outcomes, but this needs further study.

Despite decades of research supporting immune dysfunction from asbestos exposure, asbestos has not been designated as a trigger for autoimmunity (reviewed in Refs. [10,11]), and autoimmune outcomes have never been incorporated into asbestos risk assessments. We propose the possibility that this is because the literature historically has not clearly differentiated between types of asbestos in autoimmune studies, and that AA, but not chrysotile, may be an environmental trigger for SAID [11].

### 3. Theory: amphibole asbestos as a trigger for autoimmune outcomes

What is needed is a paradigm shift in the way we evaluate health effects of exposure to fibrous dusts. This will mean careful evaluation of fiber-specific risk, going beyond the commercial fibers. The data reviewed below calls for continued studies into immune dysfunction from asbestos exposure, specifically comparing amphibole with chrysotile, and strongly supports the ability of asbestos to impact ultimate disease outcomes through its immunotoxicity. Specifically, AA has been linked to serum autoantibodies [11–13], and an increased risk of systemic autoimmune diseases (SAID) [14], but chrysotile has not [9]. Interestingly, chrysotile's ability to cause cancer may result from a combination of its carcinogenicity plus its inhibition of the anti-cancer immune response [9,15], including T<sub>H</sub>1 and T<sub>H</sub>17 cytokines which are implicated in autoimmunity and are triggered by AA [9,16].

### 4. Libby's lessons

In 1999, Pulitzer-winning journalist, Andy Schneider, revealed to the world that the mining and use of asbestos-contaminated vermiculite in Libby, Montana was causing a high rate of morbidity and mortality [17]. The suffering manifested as typical asbestos-related diseases: mesothelioma, asbestosis and pleural fibrosis. However, a federally-funded screening program also revealed that an elevated proportion of the population was reporting systemic autoimmune diseases (SAID), such as Systemic Lupus Erythematosus (SLE). In 2001, a team from the University of Montana, Missoula, was asked to assist the CDC/ATSDR in screening the residents of Libby for scientific evidence of an autoimmune outcome. First, testing for antinuclear autoantibodies (ANA) was performed on serum donated from screening participants. ANA are commonly used to assist with diagnosis of SAID, and despite background levels in healthy people, they are considered a valuable tool for

screening and assessment of people with autoimmune symptoms. That study demonstrated that the frequency and titers of ANA in Libby residents were significantly higher than in an age- and sex-matched group from nearby Missoula, MT [13]. Second, the team analyzed self-reported ATSDR survey data of more than 7300 Libby screening subjects for diagnoses of SAID. In 2006, this second study associated asbestos exposure with increased risk of SLE, scleroderma and rheumatoid arthritis [14]. In 2009, a report of the ANA profiles of the Libby cohort revealed that the most common ANA patterns were consistent with SLE, with elevated frequencies of antibodies to dsDNA, RNP, and Ro52 [18]. There was also a high frequency of antibodies to topoisomerase, also called Scl-70, indicative of scleroderma. These autoantibody patterns, especially at the elevated titers seen in Libby, suggest a pathogenic process according to current thinking [19]. Subsequently, the Libby Epidemiology Research Program (LERP) found that among the 4779 patients who have undergone health screening at the Center for Asbestos Related Diseases (CARD, Libby MT), the rate of diagnosed SLE is over 1%, well above the CDC's reported U.S. prevalence of 0.05%.

### 5. Epidemiologic evidence and the imprecision of the term asbestos

Despite the emerging evidence from Libby, plus a history of studies describing similar results in other asbestos-exposed cohorts, asbestos has not yet been designated as an environmental trigger for SAID [10,20]. However, another silicate dust, crystalline silica, is strongly associated with SAID (reviewed in Refs. [21,22]). This difference triggered mechanistic studies to examine possible similar pathways to autoimmunity by both silica and asbestos, but no consensus arose, with some evidence that the immune dysfunction pathways were different [23] and some showing that they were similar [24–26]. The problem may be that the term “asbestos” is too imprecise because of the many forms of mineral fibers to which humans are exposed. When the literature was reviewed based on fiber types, a pattern emerged in which AA was linked with autoantibodies and SAID, but chrysotile was not (reviewed in Refs. [11,27]). To our knowledge, there is only one study comparing ANA frequency in cohorts exposed exclusively to amphibole or chrysotile. In that case, amphibole (LAA) increased the frequency of ANA above expected levels, but chrysotile (in a cohort of New York pipe insulators) did not [27]. There were, however, weaknesses in this study including the small size of the chrysotile cohort and in comparing a purely occupational exposure (pipe insulators) with a mixed occupational/environmental exposure (Libby). However, comparable exposure populations are rare, making such studies in humans very difficult.

## 6. Mouse studies of asbestos immunotoxicity

The immunotoxicity of asbestos starts with inflammation, driven by oxidative stress and cytokine production (Fig. 1). The effects of asbestos in mice and cell culture studies include “frustrated phagocytosis”, oxygen radical formation, inflammasome activation, DNA damage, and apoptosis [28–30]. These early outcomes of interaction with mineral fibers appear to drive the ultimate disease outcomes, and may be related to specific size, mineralogy, and chemistry of the fibers. Current studies are even finding similarities between the inflammatory effects of asbestos and elongated nanomaterials, such as nanotubes [31]. The mechanisms of AA immunotoxicity appear to be similar to those of crystalline silica, but distinct from chrysotile. For example, one group in Japan has contrasted the immune effects of silica and chrysotile asbestos, demonstrating that although silica clearly generates an immune dysfunction supportive of autoimmunity, chrysotile is immunosuppressive particularly in terms of an anti-cancer  $T_H1$  responsiveness [15,23,32]. Similar results were seen when comparing the effects of amphibole to chrysotile in mice, where chrysotile inhibited  $T_H1$  and  $T_H17$  cytokines, but AA induced them [9,16] (Fig. 2).

Studies in rodents have demonstrated the ability of AA to trigger ANA production [33,34]. In mice, immune complex deposition and kidney pathology have been noted, suggesting a lupus-like disease manifestation [16,33]. Amphibole asbestos (including both tremolite

and LAA) also triggers  $T_H17$  cytokines both *in vitro* (spleen cells) and *in vivo* (mouse serum), which are implicated in autoimmunity [9,16]. Chrysotile, however, did not trigger ANA, kidney pathology, or  $T_H17$  cytokines [9]. These studies strongly support the hypothesis that only AA is similar to silica in producing an immune dysfunction that predisposes to autoimmunity. This may clear the way for studies of AA specifically as an environmental trigger for SAID.

## 7. MCAA and autoimmune fibrosis in mice

In addition to ANA, mice produce Mesothelial Cell AutoAntibodies (MCAA) in response to LAA exposure, and MCAA are associated with excess production of pleural collagen in AA-exposed mice [35]. Critically, MCAA instilled into the peritoneal cavity of naïve (non-asbestos exposed) mice can trigger collagen deposition, suggesting that MCAA can directly contribute to serous fibrosis [35]. The idea that antibodies that bind to collagen-producing cells can contribute to fibrosis is not new. Antibodies to fibroblasts have been implicated in autoimmune fibrotic diseases such as scleroderma [36,37]. As a potential autoimmune phenomenon, therapeutic modalities for pleural fibrosis begin to emerge. Therefore, the possibility that pleural fibrosis includes an autoimmune process has precedence and public health significance.

## 8. Progressive pleural fibrosis as an autoimmune phenomenon


Another lesson learned from Libby is that pleural fibrosis is the most common manifestation of exposure and that LAA's pleural fibrosis is severe and progressive [38–40] unlike that seen with chrysotile. LAA's progressive and inflammatory pleural disease led to consideration of a potential contribution from immune dysfunction (Fig. 3).

First, we demonstrated that LAA induces MCAA, which were associated with radiographic changes in the pleura [12]. We then showed that MCAA induced collagen deposition by mesothelial cells *in vitro* [41], and that they were associated with pleural, but not interstitial, disease in a subset of CARD patients [27]. Currently, screening indicates that up to 35% of LAA-exposed subjects have MCAA, but that MCAA are rare in normal human serum (Libby Epidemiology Research Program and [27]).

## 9. Possible mechanisms of asbestos-induced autoimmune fibrosis


The above studies of anti-fibroblast and anti-mesothelial cell autoantibodies reveal that they can induce cytokine and collagen production that support fibrogenic processes. One pathway involves binding of antibodies to the Platelet-Derived Growth Factor Receptor, PDGFR- $\alpha$  [42,43]. In mice, anti-fibroblast

Fig. 1




Schematic of early cellular events and health outcomes with asbestos exposure.

Fig. 2



Hypothetical Model of Differential Effects and Outcomes of Amphibole Versus Chrysotile Exposure. Pie charts do not contain data, but represent simple models in which health outcomes for amphibole asbestos are predominated by fibrotic and autoimmune responses, and those for chrysotile tend to be cancer (mesothelioma and lung carcinomas).

Fig. 3



Schematic model for hypothetical induction of autoimmune responses through environmental exposures to amphibole asbestos.

ANA = antinuclear autoantibodies; AID = autoimmune diseases; MCAA = mesothelial cell autoantibodies.

antibodies induced by LAA were shown to bind PDGFR- $\alpha$ , and to induce a myofibroblast phenotype with STAT-1 activation, all implicated in fibrogenic pathways [44]. A study of the gene expression initiated by exposure of mesothelial cells to asbestos-induced MCAA revealed that several pathways related to fibrogenesis were triggered, including both PDGFR- $\alpha$  and STAT-1 [45]. Further, two key transcription factors were activated, C/EBP- $\beta$  and HIF- $\alpha$ , both of which play roles in collagen matrix remodeling [45]. Pharmaceutical inhibition of either transcription factor reduced the collagen expression induced by MCAA, directly relating these LAA-induced autoantibodies with collagen matrix formation and thus fibrosis [45].

Clearly, antibodies to cellular receptors such as PDGFR- $\alpha$  suggest the possibility that blocking such an interaction could be therapeutic. Using mass spectrometry of surface antigens bound by LAA-induced MCAA, one study showed that surface plasminogen is a target for MCAA [46]. A commercial antibody to plasminogen, known to block plasminogen activity, increased collagen production from cultured mesothelial cells similarly to the MCAA, suggesting that a mechanism of MCAA-induced collagen production is by blocking plasminogen activity. The plasminogen/plasmin system is known to participate in collagen matrix remodeling in other forms of fibrosis [47], thus validating inhibition of this pathway as a mechanism for MCAA-induced fibrosis.

## 10. Conclusions and implications for the future

The goal of this research direction is to improve health through recognition and prediction of disease, improved screening, and early diagnosis. Recently, a panel of experts described three areas in which criteria need to be developed for establishing associations between environmental factors and autoimmunity [48]. Two of those would be establishment of criteria for defining environmental risk factors for diseases meeting diagnostic criteria, and new environmental autoimmune disorders not meeting current diagnostic criteria. Third, there is a need to identify environmental agents that trigger autoimmune disease in

particular patients. As evidence is gathered from various research strategies, from epidemiology to animal models, “levels of confidence” can be applied to the strength of evidence. Unfortunately, we have rare opportunities to conduct prospective studies of asbestos-exposed populations. Environmental AA exposures are increasing, but we understand little about the immunologic consequences of these exposures. It seems reasonable and prudent to use emerging data from Libby and rodent studies to raise the level of concern for AA as a trigger for autoimmune disease, and to put effort and resources toward more research. Critically needed are more animal studies of fiber-specific comparisons of health outcomes, including immune dysfunction and autoimmunity in multiple strains. Also, any studies of asbestos effects in humans should include blood collection for evaluation of immune markers, including autoantibodies.

In conclusion, evaluation of asbestos health effects must a) include all mineral fibers, distinguishing chrysotile from AA, b) include non-cancer outcomes, particularly immunotoxicology and autoimmunity, and c) recognize the emerging public health risks of environmental sources of toxic mineral fibers, such as Naturally Occurring Asbestos (NOA).

## Funding

This manuscript was not supported by any specific grant from funding agencies in the public, commercial, or not-for-profit sectors, although data are referred to from the Libby Epidemiology Research Program (LERP, ATSDR TS000099-01).

## Acknowledgements

Appreciation is extended to Dr. Curtis W. Noonan, University of Montana, Missoula, for his editorial and conceptual advice for this paper. We acknowledge Dr. Brad Black and the Center for Asbestos Related Diseases in Libby, MT, and Drs. Stephen Levin and Raja Flores, Mount Sinai Medical Center, New York, for their inspiration and support of the LERP research efforts.

## Conflicts of interest

I have no conflicts of interest to declare.

## References

Papers of particular interest, published within the period of review, have been highlighted as:

- \* of special interest
- \*\* of outstanding interest

1. Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S: **Consensus report of the 2015 Weinman International Conference on Mesothelioma.** *J Thorac Oncol* 2016, **11**(8):1246–1262.
2. Carlin DJ, Larson TC, Pfau JC, Gavett SH, Shukla A, Miller A, Hines R: **Current research and opportunities to address environmental asbestos exposures.** *Environ Health Perspect* 2015, **123**(8):A194–A197.

3. Noonan CW: **Environmental asbestos exposure and risk of mesothelioma.** *Ann Transl Med* 2017, **5**(11):234. \*
4. Bayram M, Bakan ND: **Environmental exposure to asbestos: from geology to mesothelioma.** *Curr Opin Pulm Med* 2014, **20**(3):301–307.
5. Buck BJ, Goossens D, Metcalf RV, McLaurin B, Ren M, Freudenberg F: **Naturally occurring asbestos: potential for human exposure, southern Nevada, USA.** *Soil Sci Soc Am J* 2013, **77**:2192–2204.
6. Wolfe C, Buck B, Miller A, Lockey J, Weis C, Weissman D, Jones A, Ryan P: **Exposure to naturally occurring mineral fibers due to off-road vehicle use: a review.** *Int J Hyg Environ Health* 2017, **220**(8):1230–1241.
7. Seager R, Ting MF, Held I, Kushnir Y, Lu J, Vecchi G, Huang HP, Harnik N, Leetmaa A, Lau NC, Li CH, Velez J, Naik N: **Model projections of an imminent transition to a more arid climate in southwestern North America.** *Science* 2007, **316**(5828):1181–1184.
8. Bernstein DM: **The health risk of chrysotile asbestos.** *Curr Opin Pulm Med* 2014, **20**(4):366–370.
9. Ferro A, Zebedeo CN, Davis C, Ng KW, Pfau JC: **Amphibole, but not chrysotile, asbestos induces anti-nuclear autoantibodies and IL-17 in C57BL/6 mice.** *J Immunotoxicol* 2013, **11**(3):283–290. \*
10. Miller FW, Alfredsson L, Costenbader KH, Kamen DL, Nelson LM, Norris JM, De Roos AJ: **Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop.** *J Autoimmun* 2012, **39**(4):259–271. \*\*
11. Pfau JC, Serve KM, Noonan CW: **Autoimmunity and asbestos exposure.** *Autoimmune Dis* 2014, **2014**:1–11. \*
12. Marchand LS, St-Hilaire S, Putnam EA, Serve KM, Pfau JC: **Mesothelial cell and anti-nuclear autoantibodies associated with pleural abnormalities in an asbestos exposed population of Libby MT.** *Toxicol Lett* 2012, **208**(2):168–173.
13. Pfau JC, Sentissi JJ, Weller G, Putnam EA: **Assessment of autoimmune responses associated with asbestos exposure in Libby, Montana, USA.** *Environ Health Perspect* 2005, **113**(1):25–30. \*
14. Noonan CW, Pfau JC, Larson TC, Spence MR: **Nested case-control study of autoimmune disease in an asbestos-exposed population.** *Environ Health Perspect* 2006, **114**(8):1243–1247.
15. Kumagai-Takei N, Maeda M, Chen Y, Matsuzaki H, Lee S, Nishimura Y, Hiratsuka Y, Otsuki T: **Asbestos induces reduction of tumor immunity.** *Clin Dev Immunol* 2011, **2011**, 481439. 1–9.
16. Zebedeo CN, Davis C, Pena C, Ng KW, Pfau JC: **Erionite induces production of autoantibodies and IL-17 in C57BL/6 mice.** *Toxicol Appl Pharmacol* 2014, **275**(3):257–264.
17. Schneider A, McCumber D: *An air that kills: how the asbestos poisoning of Libby, Montana uncovered a National Scandal.* New York: G.P. Putnam Publishing; 2004.
18. Pfau JC, Blake DJ, Fritzler MJ: **Autoantibody profiles of an asbestos-exposed population.** In *Autoimmunity: role, regulation and disorders*. Edited by Vogel FL, Zimmermann LF, New York, NY: Nova Science Publishers; 2009:245–268.
19. Choi MY, Barber MR, Barber CE, Clarke AE, Fritzler MJ: **Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care.** *Lupus* 2016, **25**(8):838–849.
20. Barbhuiya M, Costenbader KH: **Environmental exposures and the development of systemic lupus erythematosus.** *Curr Opin Rheumatol* 2016, **28**(5):497–505.
21. Pollard KM: **Silica, silicosis, and autoimmunity.** *Front Immunol* 2016, **7**:97.
22. Brown JM, Pfau JC, Pershouse MA, Holian A: **Silica, apoptosis, and autoimmunity.** *J Immunotoxicol* 2005, **1**(3):177–187.
23. Otsuki T, Maeda M, Murakami S, Hayashi H, Miura Y, Kusaka M, Nakano T, Fukuoka K, Kishimoto T, Hyodoh F, Ueki A, Nishimura Y: **Immunological effects of silica and asbestos.** *Cell Mol Immunol* 2007, **4**(4):261–268.
24. Blake DJ, Bolin CM, Cox DP, Cardozo-Pelaez F, Pfau JC: **Internalization of Libby amphibole asbestos and induction of oxidative stress in murine macrophages.** *Toxicol Sci* 2007, **99**(1):277–288.
25. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J: **Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica.** *Science* 2008, **320**(5876):674–677.
26. Rihova Z, Maixnerova D, Jancova E, Pelcova D, Bartunkova J, Fenclova Z, Vankova Z, Reiterova J, Merta M, Rysava R, Tesar V: **Silica and asbestos exposure in ANCA-associated vasculitis with pulmonary involvement.** *Ren Fail* 2005, **27**(5):605–608.
27. Pfau JC, Serve KM, Woods L, Noonan CW: **Asbestos exposure and autoimmunity.** In *Biological effects of fibrous and particulate substances*. Springer Publications; 2015.
28. Bunderson-Schelman M, Pfau JC, Crouch R, Holian A: **Nonpulmonary outcomes of asbestos exposure.** *J Toxicol Environ Health B Crit Rev* 2011, **14**(1–4):122–152.
29. Hillegass JM, Miller JM, MacPherson MB, Westbom CM, Sayan M, Thompson JK, Macura SL, Perkins TN, Beuschel SL, Alexeeva V, Pass HI, Steele C, Mossman BT, Shukla A: **Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells.** *Part Fibre Toxicol* 2013, **10**:39.
30. Kodavanti UP, Andrews D, Schladerweiller MC, Gavett SH, Dodd DE, Cyphert JM: **Early and delayed effects of naturally occurring asbestos on serum biomarkers of inflammation and metabolism.** *J Toxicol Environ Health A* 2014, **77**(17):1024–1039. \*
31. Miozzi E, Rapisarda V, Marconi A, Costa C, Polito I, Spandidos DA, Libra M, Fenga C: **Fluoro-edenite and carbon nanotubes: the health impact of 'asbestos-like' fibres.** *Exp Ther Med* 2016, **11**(1):21–27.
32. Lee S, Matsuzaki H, Kumagai-Takei N, Yoshitome K, Maeda M, Chen Y, Kusaka M, Urakami K, Hayashi H, Fujimoto W, Nishimura Y, Otsuki T: **Silica exposure and altered regulation of autoimmunity.** *Environ Health Prev Med* 2014, **19**(5):322–329.
33. Pfau JC, Sentissi JJ, Li S, Calderon-Garciduenas L, Brown JM, Blake DJ: **Asbestos-induced autoimmunity in C57BL/6 mice.** *J Immunotoxicol* 2008, **5**(2):129–137.
34. Salazar KD, Copeland CB, Wood CE, Schmid JE, Luebke RW: **Evaluation of anti-nuclear antibodies and kidney pathology in Lewis rats following exposure to Libby amphibole asbestos.** *J Immunotoxicol* 2012, **10**(4):329–333.
35. Gilmer J, Serve K, Davis C, Anthony M, Hanson R, Harding T, Pfau JC: **Libby amphibole induced mesothelial cell autoantibodies promote collagen deposition in mice.** *Am J Physiol Lung Cell Mol Physiol* 2016, **310**(11):L1071–L1077. \*
36. Chizzolini C, Brembilla NC, Montanari E, Truchetet ME: **Fibrosis and immune dysregulation in systemic sclerosis.** *Autoimmun Rev* 2011, **10**(5):276–281.
37. Fineschi S, Cozzi F, Burger D, Dayer JM, Meroni PL, Chizzolini C: **Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts.** *Rheumatology (Oxford)* 2007, **46**(12):1779–1785.
38. Black B, Szeinuk J, Whitehouse AC, Levin SM, Henschke CI, Yankellevitz DF, Flores RM: **Rapid progression of pleural disease due to exposure to Libby amphibole: "Not your grandfather's asbestos related disease".** *Am J Ind Med* 2014, **57**(11):1197–1206.
39. Szeinuk J, Noonan CW, Henschke CI, Pfau J, Black B, Miller A, Yankellevitz DF, Liang M, Liu Y, Yip R, Linker L, McNew T, Flores RM: **Pulmonary abnormalities as a result of exposure to Libby amphibole during childhood and adolescence – the**

- pre-adult latency study (PALS). *Am J Ind Med* 2017, **60**(1): 20–34.
40. Whitehouse AC: **Asbestos-related pleural disease due to tremolite associated with progressive loss of lung function: serial observations in 123 miners, family members, and residents of Libby, Montana.** *Am J Ind Med* 2004, **46**(3):219–225.
  41. Serve KM, Black B, Szeinuk J, Pfau JC: **Asbestos-associated mesothelial cell autoantibodies promote collagen deposition in vitro.** *Inhal Toxicol* 2013, **25**(14):774–784.
  42. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A: **Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.** *N Engl J Med* 2006, **354**(25):2667–2676.
  43. Gabrielli A, Svegliati S, Moroncini G, Luchetti M, Tonnini C, Avvedimento EV: **Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets.** *Autoimmun Rev* 2007, **7**(2):121–126.
  44. Pfau JC, Li S, Holland S, Sentissi JJ: **Alteration of fibroblast phenotype by asbestos-induced autoantibodies.** *J Immunotoxicol* 2011, **8**(2):159–169.
  45. Gilmer J, Harding T, Woods L, Black B, Flores R, Pfau JC: **Mesothelial cell autoantibodies upregulate transcription factors associated with fibrosis.** *Inhal Toxicol* 2017, **29**(1): 10–17.
  46. Hanson R, Evilia C, Gilmer J, Woods L, Black B, Flores R, Pfau JC: **Libby amphibole-induced mesothelial cell autoantibodies bind to surface plasminogen and alter collagen matrix remodeling.** *Physiol Rep* 2016, **4**(15):1–12.
  47. de Giorgio-Miller A, Bottoms S, Laurent G, Carmeliet P, Herrick S: **Fibrin-induced skin fibrosis in mice deficient in tissue plasminogen activator.** *Am J Pathol* 2005, **167**(3):721–732.
  48. Miller FW, Pollard KM, Parks CG, Germolec DR, Leung PS, Selmi C, Humble MC, Rose NR: **Criteria for environmentally associated autoimmune diseases.** *J Autoimmun* 2012, **39**(4): 253–258.